| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
|
|
Today’s Big NewsFeb 12, 2025 |
| By Angus Liu In the last few years, Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry. With multiple programs now nearing proof-of-concept readouts, yet still “not happy about the pace” of development, Astellas is shifting its focus more to later-stage opportunities, chief strategy officer Adam Pearson said. |
|
|
|
By Darren Incorvaia After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts. |
By Conor Hale Abbott had claimed that Sinocare’s iCan i3 wearable CGM was too similar to its FreeStyle Libre sensor—in this case, a small, white disc. |
By Nick Paul Taylor Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects into touch. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.
|
|
By Nick Paul Taylor Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, promoting him to chief commercial officer after a year in which sales of the gene therapy fell short of expectations. |
By Fraiser Kansteiner The FDA on Wednesday gave the thumbs up to a tablet formulation of Roche's Evrysdi to treat spinal muscular atrophy in adults and children ages 2 and older. The new tablets, which Roche plans to launch in the coming weeks, are expected to offer patients greater flexibility in how they manage their disease. |
By Gabrielle Masson A federal judge has issued a temporary pause across all states on the new NIH order that caps “indirect costs” for research grants—a move designed to slash costs by $4 billion per year. |
By Zoey Becker The company's HIV sales surged 16% during the fourth quarter, setting the scene for its anticipated summer launch of long-acting PREP candidate lenacapivir. |
By Conor Hale In Monday’s trading, Pacific Biosciences and 10x Genomics each saw their stock prices dive by 13% to 14%, while Illumina has been recovering from being caught up in the tariff battle between the U.S. and China. |
By James Waldron Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the U.S. pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based immunotherapies. |
By Darren Incorvaia Less than a month after researchers unveiled that a “ticking DNA clock” is behind Huntington’s disease, scientists have now identified an antisense oligonucleotide that can slow down the disease-causing gene expansion process. |
By Andrea Park So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer awareness campaigns. |
By Kevin Dunleavy After Merck KGaA's recent confirmation that it's in discussions to acquire SpringWorks Therapeutics, the Connecticut rare disease specialist has boosted its value with a new FDA nod. |
By Andrea Park To guide children through an atypical hemolytic uremic syndrome diagnosis and subsequent treatment, Alexion Pharmaceuticals has released an interactive storybook aimed at “demystifying” the disease for 6- to 10-year-olds. |
By Conor Hale The neurostimulation company, based outside Minneapolis, said in a filing that it had received a civil investigative demand, or CID, Jan. 17 from the U.S. district attorney’s office in Minnesota that was also related to potential violations of federal anti-kickback law. |
By Darren Incorvaia Michigan-based clinical research organization MMS is boosting its data science power with a new purchase from the U.K. The firm has acquired the Northern Irish data science company Exploristics, gaining access to its cloud-based statistical modeling and simulation platform. |
Fierce podcastsDon’t miss an episode |
| | A recent report, released at this year’s J.P. Morgan Healthcare Conference, lays out the high-growth potential of the women’s health market and its promised return on investment. |
|
|---|
|
|
|
Tuesday, February 25, 2025 | 2pm ET / 11am PT Discover how a direct-to-individual approach to real-world data (RWD) is transforming obesity treatment insights. Learn how the right engagement strategies enable effective tracking of GLP-1 use, adherence, and outcomes, leveraging wearable and multi-modal data for predictive modeling and early interventions. Join us to explore new ways to enhance patient understanding. Register now.
|
|
| WhitepaperThis paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
